2024-09-18 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company that researches, develops, and commercializes medicines for the treatment of life-threatening diseases. 

**1. Performance Comparison with S&P 500 (VOO):**

* **Cumulative Return:** GILD (20.45%) has significantly underperformed VOO (89.02%).
* **Relative Divergence:** The current relative divergence is -68.57%, indicating GILD is currently 68.57% behind VOO. This places GILD within the 21.42% percentile of its historical performance compared to VOO.

**2. Recent Price Movements:**

* **Closing Price:** $83.16
* **Moving Averages:**
    * 5-Day: $82.3
    * 20-Day: $78.75
    * 60-Day: $74.43

The stock is currently trading above all three moving averages, indicating potential upward momentum.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 78.81, indicating the stock is in overbought territory.
* **PPO (Percentage Price Oscillator):** 0.41, suggesting a bullish trend.
* **Delta_Previous_Relative_Divergence:** +9.31, indicating a short-term uptrend.
* **Expected Return:** 19.91%, representing the potential 5-year return based on the current investment.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for the quarter ended 2024-08-08 showed EPS of $1.29, exceeding analyst expectations. Revenue for the quarter came in at $6.95 billion, also surpassing expectations. This positive earnings beat suggests strong underlying fundamentals and potential for continued growth. 

**5. Summary:**

GILD has significantly underperformed the market in the past, showing a cumulative return that is significantly lower than the S&P 500. However, recent price movements and technical indicators suggest potential upward momentum. The company's recent earnings report exceeded expectations, indicating positive growth prospects. The stock is currently in overbought territory, but its expected return remains strong.

**6. Recommendations:**

While GILD's past performance has been underwhelming, recent positive indicators and earnings suggest a potential turning point. It may be worth considering GILD for investors seeking long-term growth potential, however, it is important to monitor the stock closely for potential overbought conditions and adjust investments accordingly. 
